Sign in
Not yet taking people in HungaryPhase 4

Broncho-Vaxom to reduce flare-ups in people with chronic obstructive pulmonary disease

Tests Broncho-Vaxom for fewer flare-ups in adults with chronic obstructive pulmonary disease.

Key facts

Who runs it
Semmelweis University
Where
Budapest VIII and Pécs, HungarySee the 2 sites
Registry title
The effect of Broncho-Vaxom on the COPD exacerbations in terms of lung function, lung mechanics, immune state, body composition, quality of life and physical activity.
Status
Not yet recruiting
Phase
Phase 4
People taking part
260 people, planned
Started
1 Feb 2026
Expected to end
31 Dec 2028
Type of study
Interventional
Record updated
13 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 to 80 with confirmed COPD who had repeated flare-ups despite standard treatment. It tests Broncho-Vaxom.

Age
40 to 80 years (the registry header lists a minimum age of 18 years).
Sex
Women and men can join.
Disease stage
Confirmed COPD with FEV1 above 20% and below 70% of predicted. Lung function must improve by less than 12% after a reversibility test. At least two moderate flare-ups, or one severe flare-up needing hospital care, despite standard treatment.
Earlier treatment
Must be taking standard COPD treatment as in the GOLD guidelines. Must not have taken immunosuppressants or oral steroids in the last month, antibiotics in the last 4 weeks, or bacterial lysate in the last 12 months (at least 4 weeks before entering).

Main reasons for not taking part

  • Not following standard COPD treatment properly
  • Cannot walk far enough to come to the visits
  • Allergy or hypersensitivity to Broncho-Vaxom
  • Recent use of immunosuppressants, oral steroids, antibiotics or bacterial lysate
  • Any other condition or situation the investigator thinks could confuse the results or make taking part not in the person's interest

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Has confirmed diagnosis of COPD
  • The participant provides documented informed consent/assent for the study
  • At least two moderate or one severe exacerbations requiring hospitalization (for 3 days steroid therapy or antibiotic therapy due to exacerbation), despite adherence to standard treatment as outlined in the GOLD guidelines
  • FEV1>20%pred and FEV1<70%pred
  • BMI: 18 kg/m2 – 40 kg/m2
  • Female and male patients between 40 years and 80 years
  • Heavy smoking anamnesis: >20 years smoking history
  • Not reversible <12%pred FEV1 with reversibility test
  • Male participants agree to use contraception method through the study conduct
  • Contraceptive use by women and men should be consistent with local regulation regarding the methods of contraception for those participating in studies

Who cannot take part

  • Patients with inadequate compliance with standard therapies for COPD
  • Patients who take immunosuppressants or oral corticosteroids within 1 month before entering the study
  • Patients who take antibiotics within 4 weeks before entering the study
  • Patients who take bacterial lysate in the previous 12 months at least 4 weeks before entering the study
  • Has a hypersensitivity to Broncho-Vaxom
  • Has a history or current evidence of any condition, therapy or laboratory abnormality or other circumstances that might confound the results of the study, interfere with the participant’s participation for the full duration of the study, such that is not in the best interest of the participant to participate, in the opinion of the investigator
  • Patients who are unable to walk enough distance to come to the visit

Where in Hungary

  • Semmelweis UniversityBudapest VIII, HungaryNot yet recruiting
  • University of PecsPécs, HungaryNot yet recruiting

About the trial

What the trial wants to find out

To evaluate the efficacy of Broncho-Vaxom in reducing the rate of moderate (managed at home) and severe (requiring hospitalization) exacerbations in COPD patients during the 6-month treatment period and the subsequent 6-month observation phase.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
The effect of Broncho-Vaxom on the COPD exacerbations in terms of lung function, lung mechanics, immune state, body composition, quality of life and physical activity.
Plain-language title
Broncho-Vaxom to reduce flare-ups in people with chronic obstructive pulmonary diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
13 March 2026